

PTO/SB/08A (10-96)

+

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

JUL 21 2004

**DISCLOSURE**  
**APPLICANT**  
**PATENT & TRADEMARK**

**Complete if Known**


<b>Application Number</b>	10/076,191
<b>Filing Date</b>	02-14-2002
<b>First Named Inventor</b>	SMITH
<b>Group Art Unit</b>	1614
<b>Examiner Name</b>	Dwayne C. Jones
<b>Attorney Docket Number</b>	USAV2001/0002 - US - NP

Sheet	1	of	2
-------	---	----	---

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Foreign Patent Document		Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Total Pages
		Office <sup>3</sup>	Number <sup>4</sup>					
		EP	0287982		Hoechst Roussel Pharma	10-26-1988		
		EP	0683165		Hoechst Roussel Pharma	22-11-1995		
		EP	0415103		Hoechst Roussel Pharma	06-03-1991		
		EP	0731108		Boehringer Mannheim GmbH	09-11-1996		
		DE	43 25 491		Boehringer Ingelheim KG	02-02-1995		
		WO	WO01/04091		Orlho McNeil Pharm Inc.	01-18-2001		
		WO	WO96/14066		Novo Nordisk	05-17-1996		

Wetland (me)

9/13/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	10/076,191	
			Filing Date	02-14-2002	
			First Named Inventor	SMITH	
			Group Art Unit	1614	
			Examiner Name	Dwayne C. Jones	
Sheet	2	of	2	Attorney Docket Number	USAV2001/0002 - US - NP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		C.T. BEVER, JR., The Current Status of Studies of Aminopyrides in Patients with Multiple Sclerosis, Annals of Neurology, Boston, MA, Vol. 36, 1994, pp. S118-S121	
		L. TANG et al., 4-Aminopyridine Derivatives: A Family of Novel Modulators of Voltage-Dependent Sodium Channels, Drug Development Research, Vol. 44, No. 1, May 1998, pp. 8-13	
		L. TANG et al., Effects of besipirdine at the voltage-dependent sodium channel, British Journal of Pharmacology, Vol. 116, No. 5, 1995, pp. 2468-2472	
		M ABOU-GHARBIA et al., IV Congress of the ECNP, Aggression and anxiety are the first components to respond to antidepressant therapy, Drug News and Perspectives, Vol. 4, No. 10, Dec. 1, 1991, pp. 647-650	
		P. Villoslada et al., Human Nerve Growth Factor Protects Common Marmosets against Autoimmune Encephalomyelitis by Switching the Balance of T Helper Cell Type 1 and 2 Cytokines within the Central Nervous System, Journ. of Experimental Medicine, Vol. 191, No. 10, 15 May 2000, pp. 1799-1806	
		R.M. EGLEN et al., Muscarinic receptor ligands and their therapeutic potential, Current Opinion in Chemical Biology, Vol. 3, No. 4, August 1999, pp. 426-432	
		W.J. MYSIW et al., Medications To Enhance Cognitive Functioning, Physical Medicine and Rehabilitation Clinics of North America, 1997, pp. 781-800	

Examiner Signature		Date Considered	9/13/04
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.